<DOC>
	<DOC>NCT00743938</DOC>
	<brief_summary>The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib</brief_summary>
	<brief_title>A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>ECOG PS of 0 or 1 Histologically confirmed NSCLC Adequate amount of tumor (archived or fresh) for biomarker evaluation Received one to two regimens of chemotherapy (with at least one platinumcontaining) Serum creatinine of less than 1.0 mg/dL or a 24 hour creatinine clearance of greater than 60 mL/min Stable control of blood pressure on agents other than calcium channel blockers Women of childbearing potential must avoid pregnancy or maintain adequate contraception Must be able to swallow pills and take the medications at the same time every day on an empty stomach ECOG PS 2 or greater Women unwilling to avoid pregnancy or use adequate contraception Symptomatic brain metastases Recent history of TIA, CVA, or thrombotic/thromboembolic event (within 6 months) History of hemoptysis greater than 10 mL/day Significant cardiovascular disease Uncontrolled diarrhea, Crohn's disease, ulcerative colitis, or any malabsorptive disease History of use of other TKIs Uncontrolled hypertension HIV+</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>